Welcome to our dedicated page for Immutep news (Ticker: IMMP), a resource for investors and traders seeking the latest updates and insights on Immutep stock.
Immutep Limited reports clinical and corporate developments as a clinical-stage biotechnology company developing Lymphocyte Activation Gene-3 (LAG-3) related immunotherapies for cancer and autoimmune diseases. Its updates center on eftilagimod alfa (efti), a LAG-3 immunotherapy evaluated in cancer studies, and IMP761, a LAG-3 agonist antibody for autoimmune disease.
Recurring company news covers trial results and changes across programs such as TACTI-004, INSIGHT-003 and EFTISARC-NEO, FDA orphan drug designation for efti in soft tissue sarcoma, scientific-conference abstracts, development and commercialization collaborations, quarterly activities reports, cash runway commentary and Nasdaq ADR listing compliance matters.
Immutep Limited (ASX: IMM; NASDAQ: IMMP) has announced that data from its Phase II TACTI-002 trial will be presented at the Society for Immunotherapy of Cancer (SITC) Annual Meeting 2021, held in Washington, US, from November 10-14, 2021. Additionally, results from the Phase IIb AIPAC trial will be shared as a late breaker poster presentation. The poster abstracts will be published on November 9, 2021, followed by new data on November 12, 2021. TACTI-002 evaluates efti with pembrolizumab in treating head and neck cancer patients.
Immutep Limited (ASX: IMM; NASDAQ: IMMP) has announced a significant cash boost of €2,126,617 (~ A$3,430,952) from the French Government via its Crédit d’Impôt Recherche scheme. This R&D tax incentive benefits the company’s European research efforts conducted during the 2020 calendar year. Additionally, Immutep received a A$1,155,055 rebate from the Australian Federal Government for similar activities. The funds will aid in the global clinical development of eftilagimod alpha and the preclinical development of IMP761.
Immutep Limited (ASX: IMM; NASDAQ: IMMP) is set to present at key investor conferences, highlighting its advancements in LAG-3 related immunotherapy for cancer and autoimmune diseases. On September 29, 2021, CEO Marc Voigt will participate in the Cantor Fitzgerald Virtual Global Healthcare Conference. Additionally, an informal discussion led by Goldman Sachs will occur on October 7, 2021, featuring CEO Voigt. Immutep's lead product, eftilagimod alpha (IMP321), is an innovative antigen presenting cell activator currently being explored.
Immutep, a biotechnology company focusing on LAG-3 immunotherapy, will present final Overall Survival (OS) data from its Phase IIb AIPAC trial for eftilagimod alpha (efti) in metastatic breast cancer at the SITC Annual Meeting 2021 from November 10-14. This late breaker poster presentation follows interim data showcased at the San Antonio Breast Cancer Symposium in December 2020, demonstrating a median survival benefit of +2.7 months for the efti group. The AIPAC trial enrolled 227 patients and aims to enhance immune responses against tumors.
Immutep Limited (NASDAQ: IMMP) has successfully completed patient recruitment for Stage 2 of Part B in its Phase II TACTI-002 clinical trial, focusing on PD-1/PD-L1 refractory non-small cell lung cancer (NSCLC). A total of 154 out of an expected 183 patients are now enrolled, with ongoing recruitment for the expansion stage of Part A. Preliminary data presented indicated a positive risk-benefit ratio in this challenging patient population. Further results are anticipated by early 2022.
Immutep Limited (NASDAQ: IMMP) announced that its Chinese partner, EOC Pharma, plans to expand its clinical trial pipeline for eftilagimod alpha (efti) in China. EOC is set to initiate a new clinical trial combining efti with an anti-PD-1 therapy in the first half of 2022. This follows promising data from ASCO 2021 and EOC's earlier Phase II trial in metastatic breast cancer, slated for the second half of 2021. EOC, responsible for efti's development in Greater China, has received positive feedback for its manufacturing processes from China's regulatory authorities.
Immutep Limited (ASX: IMM; NASDAQ: IMMP) has announced the grant of patent no. ZL201580013695.X by the Chinese Patent Office for LAG525, an antibody molecule aimed at treating cancer and infectious diseases. This patent follows prior grants in Australia, the U.S., Europe, and Japan. LAG525, a humanized form of IMP701, is currently being evaluated in clinical trials in collaboration with Novartis AG. The patent, set to expire on March 13, 2035, is co-owned by Novartis and Immutep S.A.S.
Immutep has announced that the first patient has been enrolled and dosed in the INSIGHT-003 trial, evaluating a triple combination therapy for metastatic non-small cell lung carcinoma. This innovative approach combines Immutep’s lead product candidate, eftilagimod alpha (efti), with standard chemotherapy and anti-PD-1 therapy. The trial aims to recruit up to 20 patients, with initial results expected in 2022, marking a significant milestone in cancer treatment research.
Immutep Limited has entered late-stage development in the LAG-3 immunotherapy space, focusing on its lead product, eftilagimod alpha (efti). Recent data presented at ASCO highlights its efficacy in treating non-small cell lung cancer (NSCLC) and head and neck squamous cell carcinoma (HNSCC). Immutep is collaborating with Merck KGaA for a new trial evaluating efti with bintrafusp alpha. The company plans to initiate a Phase III study in metastatic breast cancer, while cash reserves have increased to $60.59 million as of June 30, 2021.
Immutep Limited (ASX: IMM; NASDAQ: IMMP) has received FDA and IRB approval to launch the TACTI-003 trial, assessing the efficacy of its lead product candidate, eftilagimod alpha, in combination with KEYTRUDA in first-line treatment for Head and Neck Squamous Cell Carcinoma (HNSCC). Recruitment for the trial, which will include around 154 patients, is set to begin this quarter, with locations across Australia, Europe, and the U.S. Immutep aims to evaluate overall response rates and other efficacy metrics in this pivotal study.